Modeling Alzheimer's risk using human TREM2-knockout microglia
Amanda McQuade from Dr. Mathew Blurton-Jones’s lab discusses her protocol for differentiating microglia from induced pluripotent stem cells (iPSCs) and the use of these microglia in vivo and in vitro to uncover the mechanisms of immune activation and neurodegeneration in Alzheimer’s disease.
Amanda McQuade from Dr. Mathew Blurton-Jones’s lab discusses her protocol for differentiating microglia from induced pluripotent stem cells (iPSCs) and the use of these microglia in vivo and in vitro to uncover the mechanisms of immune activation and neurodegeneration in Alzheimer’s disease. Based on the 2020 Nature Communications paper "Gene Expression and Functional Deficits Underlie TREM2-Knockout Microglia Responses in Human Models of Alzheimer’s Disease"
Publish Date:
February 11, 2021
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.